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Pasi Soininen6,7, Zeneng Wang8, Mika Ala-Korpela6,7,9, Stanley L. Hazen8, Markku Laakso4,5 and Aldons J. Lusis1,10,11*
Abstract
Background: The gut microbiome is a complex and metabolically active community that directly influences host
phenotypes. In this study, we profile gut microbiota using 16S rRNA gene sequencing in 531 well-phenotyped
Finnish men from the Metabolic Syndrome In Men (METSIM) study.
Results: We investigate gut microbiota relationships with a variety of factors that have an impact on the
development of metabolic and cardiovascular traits. We identify novel associations between gut microbiota and
fasting serum levels of a number of metabolites, including fatty acids, amino acids, lipids, and glucose. In particular, we
detect associations with fasting plasma trimethylamine N-oxide (TMAO) levels, a gut microbiota-dependent metabolite
associated with coronary artery disease and stroke. We further investigate the gut microbiota composition and
microbiota–metabolite relationships in subjects with different body mass index and individuals with normal or altered
oral glucose tolerance. Finally, we perform microbiota co-occurrence network analysis, which shows that certain
metabolites strongly correlate with microbial community structure and that some of these correlations are specific for
the pre-diabetic state.
Conclusions: Our study identifies novel relationships between the composition of the gut microbiota and circulating
metabolites and provides a resource for future studies to understand host–gut microbiota relationships.
Keywords: Host-microbiota interactions, TMAO, Metabolic traits, Serum metabolites, Type 2 diabetes
Background
Multiple studies in humans and animal models have
established that the gut microbiota contribute signifi-
cantly to a variety of cardio-metabolic traits, including
obesity, type 2 diabetes (T2D) [1–3], insulin resistance
[4–7], atherosclerosis, and heart failure [8–10]. A growing
body of evidence shows that microbial metabolites have a
major influence on host physiology. The best known bac-
terial fermentation products are short chain fatty acids
(SCFAs) such as acetate, butyrate, and propionate, which
exert several effects, including maintenance of gut barrier
function and providing a source of energy for colono-
cytes and bacterial communities (reviewed in [11]).
Another example is trimethylamine-N-oxide (TMAO),
a metabolite derived from dietary choline and carnitine
through the action of gut microbes. TMAO plays an im-
portant role in several cardio-metabolic phenotypes and is
associated with chronic kidney disease [8, 9, 12, 13].
The majority of published studies thus far have fo-
cused on describing the gut microbiome profile changes
between specific disease groups and control individuals.
These findings usually explain dysbiosis states related to
end phenotypes and are not well powered to discover
alterations that are present in the general population
and can ultimately affect the development of common
complex diseases. A growing body of evidence suggests
that a variety of intrinsic and environmental factors,
such as long-term dietary patterns and host physiology
and genetics, significantly affect the structure and func-
tional capabilities of gut microbial communities [14–17].
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Recently, two large-scale studies from Europe charac-
terized the gut microbiota composition and variation in
subjects collected from the general population [18, 19].
Rich metadata on various health and lifestyle factors
showed several associations that impact the variation of
the gut microbiome in the general population. The
Netherland cohort study also showed the contribution
of gut microbiota to body mass index (BMI) and lipid
variation, highlighting its role in the regulation of meta-
bolic processes and cardiometabolic diseases [20]. To
date, however, no population-based studies have been
performed to assess the association between microbiota
and a large spectrum of cardiometabolic traits.
In the current study we performed systematic analysis
of the gut microbiome and a variety of metabolically
relevant traits in 531 middle-aged Finnish men, collected
from the general population of the METabolic Syndrome
In Men (METSIM) study [21]. All subjects from this
population-based cohort have been extensively charac-
terized for a variety of cardiovascular and metabolic
traits, including 2-h oral glucose tolerance test (OGTT),
insulin resistance, BMI, and serum metabolites such as
fatty acids, lipids, amino acids, glycolysis precursor metab-
olites, and ketone bodies. We identified several significant
relationships, particularly between gut microbiota and
circulating serum metabolites. In addition, we examined
the fasting plasma levels of the microbiota-dependent
metabolite TMAO. Several observed relationships were
further supported by operational taxonomy unit (OTU)-
based co-occurrence network analysis. Finally, we also
assessed microbiome–metabolite interactions in subjects
with extreme BMI and in a pre-diabetic stage based on an
impaired fasting glucose tolerance test.
Results
Landscape of the METSIM gut microbiome
Our study included 531 individuals, representing a sub-
cohort who participated in a follow-up study from the
METSIM cohort (total cohort n = 10,000). This general
population-based study cohort, consisting of males aged
45–70 years, was collected from Eastern Finland and has
been extensively phenotyped for a variety of metabolic
parameters (Additional file 1: Table S1) [21]. Stool sam-
ples for microbiota analysis were collected during a clin-
ical visit together with fasting blood samples. Baseline
characteristics for each study participant are summarized
in Table 1.
We first characterized the phylogenetic variation across
samples at different taxonomic levels. We sorted sequences
into 1148 OTUs (≥97% identity). Of these OTUs, 321 were
present in at least 50% of the samples. As expected, we ob-
served considerable variation in the abundance of taxa
in the METSIM fecal microbial communities, indicating
a typical Western diversity profile where Firmicutes
(mean = 53.43%, range = 12.9–94.1%) and Bacteroidetes
(mean = 40.80%, range = 0.11–85.9%) were the domin-
ant phyla (Additional file 1: Table S2; Additional file 2:
Figure S1a). Overall, we detected ten bacterial phyla
and one archaeal phylum. Forty percent of individuals
contained archaeal taxa from phylum Euryarcheota and
genus Methanobrevibacter (0.15%, 0–6.7%). The most
dominant bacterial families (90% of total sequences) belong
to Bacteoridacea (28% of total sequences), Ruminococcacea
(20% of total sequences), and Lachnospiracea (16% of total
sequences) (Additional file 2: Figure S1c). At the genus
level, Bacteroides was the most dominant and variable phy-
lotype across 531 METSIM samples ranging from 0.1 to
85.6%, in agreement with previous results [22, 23].
We first assessed how variable the gut microbial com-
position was in the METSIM cohort in terms of micro-
bial diversity and richness. The microbial richness,
which refers to the number of OTUs per individual, ex-
hibited on average 329 OTUs per individual, ranging
from 108 to 474 (Additional file 1: Table S3). Based on
unconstrained canonical analysis of genus-level commu-
nity composition (see “Methods”), we found that the
main genera driving diversity in the gut landscape are
Bacteroides, an unclassified Ruminococcaceae genus, and
Prevotella (Fig. 1a). This is consistent with other
population-based gut microbiome studies, showing that
these three genera are major contributors to community
variation and define previously proposed enterotypes
[18, 23]. However, our data support continuous rather
than distinct clusters, in agreement with recently pub-
lished data [24].
Table 1 Characteristics of 531 METSIM subjects
Clinical trait Average Standard deviation
Age (years) 61.97 5.45
Body mass index (kg/m2) 27.92 3.60
Waist to hip ratio (cm) 0.998 0.06
Fat mass (%) 25.79 6.93
OGTT fasting plasma glucose (mmol/l) 5.77 0.49
OGTT 30 min plasma glucose (mmol/l) 9.35 1.49
OGTT 120 min plasma glucose (mmol/l) 5.96 1.91
OGTT fasting plasma insulin (mU/l) 9.43 5.97
OGTT 30 min plasma insulin (mU/l) 65.20 42.79
OGTT 120 min plasma insulin (mU/l) 48.01 66.76
HbA1c (%) 5.6 0.29
Systolic blood pressure (mmHg) 130.12 13.51
Diastolic blood pressure (mmHg) 82.35 7.84
HOMA-IR 2.47 1.69
Hba1c glycated hemoglobin, HOMA-IR homeostatic model assessment of
insulin resistance
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Metabolite associations with gut microbiota richness and
diversity
The METSIM cohort has been studied for a variety of
cardiovascular and metabolic traits, providing an oppor-
tunity to identify potential relationships with gut micro-
biota composition. Using a nuclear magnetic resonance
(NMR) spectroscopy platform [25], we quantified a
broad molecular signature of the systemic serum metab-
olite profiles, such as lipids, fatty acids, glycolysis-related
metabolites, ketone bodies, and amino acids. A list of
the traits we examined is presented in Additional file 1:
Table S1.
We first investigated whether bacterial diversity and
richness were correlated with 57 traits (Additional file 1:
Table S1). After adjustment for age and treatment, 37
traits were associated with inter-individual distance of
microbial composition (Bray-Curtis distance) at a false
discovery rate (FDR) of 0.1, together explaining 14.1% of
the variation in composition distance (Additional file 1:
Table S4). Figure 1b shows the traits that contribute the
highest variation in microbial composition distance.
Among the associations we detected, acetate showed the
strongest effect on the variation in microbial diversity
and the richness was positively correlated with glutam-
ine, glycated hemoglobin (Hba1c), and acetate levels
(FDR <0.1) (Fig. 1b, c; Additional file 1: Tables S4
and S5; Additional file 2: Figure S2).
Metabolite associations with gut microbiota composition
We next performed multivariate association analysis
between each trait with 91 unique taxa and 321 OTUs
(shared in 50% of individuals). When adjusted for age
and treatment, we identified 140 associations between
26 traits and 72 unique bacterial OTUs at a FDR of 0.05
(Additional file 1: Table S6). Overall, 51 OTUs were sig-
nificantly associated with different fatty acids, 33 OTUs
a
b
c
Fig. 1 Microbial community variation in the METSIM cohort. a Top contributors to community variation as determined by canonical correspondence
analysis on unscaled genera abundances, plotted on the first principal component (PC) dimensions (arrows scaled to contribution). b The top seven
metabolite contributors to microbiome community variation. c A total of 32 out of 60 factors (60%) explained a total of 13% of variance of the gut
microbiome according to Bray–Curtis distance. TG triglycerides, FA fatty acids, DHA docosahexaenoic acid, MUFA monounsaturated fatty acid, PUFA
polyunsaturated fatty acid
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with ketone bodies, 19 OTUs with amino acids and
glycolysis-related metabolites, nine OTUs with glycopro-
tein acetyls, six OTUs with choline pathway metabolites,
and three OTUs with HbA1c levels (Additional file 1: Table
S6; Additional file 2: Figure S3). At the taxonomy level, we
identified a total of 40 significant associations between 17
traits and 23 unique taxa with FDR <0.05: 19 taxa were as-
sociated with fatty acids, nine with ketone bodies, five with
glycolysis-related metabolites, three with amino acids, two
with glycoprotein acetyls, and one each with betaine and
TMAO (Fig. 2; Additional file 1: Table S7).
The strongest associations with both taxonomy and
unique bacterial OTUs were with acetate and glutamine
levels, indicating a strong overlap between associations
detected with diversity and richness. Acetate is the most
common SCFA in the human colon, produced in the large
intestine by anaerobic intestinal microbiota through fer-
mentation of non-digestible carbohydrate. In total, 28
unique OTUs and eight unique taxa were associated with
serum acetate levels with FDR <0.05 (Fig. 2; Additional
file 1: Tables S6 and S7). Increased acetate levels were
associated with higher abundances of phylum Tenericutes
(mainly represented by order RF-39), family Christensenel-
laceae, unclassified Clostridales, Peptococcaceae, and
several members of family Clostridiaceae, whereas re-
duced levels were associated with higher abundances of
Blautia and genus Oscillospira (Additional file 1: Table S6;
Additional file 2: Figure S3). Acetate was also strongly cor-
related with other traits. For example, a significant positive
correlation was detected with polyunsaturated fatty acids,
such as omega-6 and 18:2 linoleic acids and with serum
cholesterol and TMAO levels, whereas a negative correl-
ation was detected with several amino acids (alanine, tyro-
sine, isoleucine, and leucine), glycolysis precursors (lactate
and pyruvate), and glycoprotein acetyl levels (FDR <0.05)
(Additional file 1: Table S8).
Western diets tend to have a high fat content, and in-
creased fat consumption is associated with obesity, insu-
lin resistance, and metabolic syndrome [26]. It has been
shown that high-fat content food perturbs gut micro-
biota and induces pro-inflammatory signaling [3, 27].
We identified several significant associations with vari-
ous fatty acids, accounting altogether for 41% of all tax-
onomy level (19 out of 46) and 33.8% of all OTU level
(51 out of 151) associations (Fig. 2; Additional file 1:
Tables S5 and S6; Additional file 2: Figure S3). At both
the taxa and OTU levels, the most significant associa-
tions were observed with the abundance of members of
the genus Blautia and phylum Tenericutes. The abun-
dance of Blautia was positively associated with saturated
and monounsaturated fatty acids and negatively associ-
ated with degree of unsaturation and polyunsaturated
fatty acids, including omega-3, 22:6 docosahexaenoic
acid, omega-6, and 18:22 linoleic acids. In contrast, op-
posite associations with the same traits were detected
with phylum Tenericutes, family Peptococcaceae, and
genus Bacteroides (Fig. 2).
Multiple significant associations were detected with
glycolysis-related metabolites and with amino acids
(Fig. 2). For example, fasting glucose levels were strongly
Fig. 2 Associations between microbiota taxa and circulating serum metabolites. Serum metabolite concentrations were measured from fasting
samples using NMR or LC-MS/MS. They were then associated with microbial taxa following adjustment for age and treatment of the subjects.
*Ruminococcus from the family Lachnospiraceae; **Ruminococcus from the family Ruminococcaceae. CI confidence interval, DHA docosahexaenoic
acid, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid
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associated with unclassified Coriobacteriaceae and seve-
ral OTUs from Blautia were positively associated with
pyruvate and glycerol. This is in line with a recent
finding showing that members of Coriobacteriacea are
depleted in individuals with diabetes and impaired glu-
cose tolerance [28]. One of the strongest associations
between amino acids and gut microbiota was detected
with glutamine levels, where several species from unclas-
sified Clostridales were positively correlated with in-
creased glutamine concentrations (Fig. 2; Additional file 2:
Figure S3). In addition, the branch-chain amino acids
(BCAAs) isoleucine and valine were negatively associated
with the abundance of Christensenellaceae and positively
associated with Blautia. Recent studies have shown that
glutamine supplementation alters gut microbiota compos-
ition and improves glucose tolerance and obesity [29, 30].
In contrast, BCAAs and other hydrophobic amino acids,
including alanine and the aromatic amino acids phenyl-
alanine and tyrosine, have been shown to be elevated in
individuals with metabolic disorders. Our data support
these observations showing significantly elevated glutam-
ine and reduced BCAAs in individuals with low BMI and
elevated BCAAs in individuals with high homeostatic
model assessment of insulin resistance (HOMA-IR) values
(Additional file 2: Figure S4).
Recently, population-based cohort studies from the
Netherlands investigated the contribution of gut micro-
biota to the variation of blood lipids and BMI [19, 20].
Here we confirmed associations with triglyceride (TG)
levels, showing that higher abundances of genus Metha-
nobrevibacter from Archaea (P = 4.4 × 10−4), Tenericutes
(P = 0.0022), Peptococcaceae (P = 0.0098), and Christen-
senellaceae (P = 0.0123) correlate with lower TG levels.
Although some other associations with high-density lipo-
protein (HDL), low-density lipoprotein (LDL), and BMI
were shared between our study and the Netherlands co-
hort study, after correction for multiple comparisons these
associations were no longer significant (FDR >0.1; data
not shown).
Associations with TMAO, a metabolite derived from gut
microbiota
Recent studies have revealed associations of gut
microbiota-dependent metabolite TMAO with the
development of cardiometabolic and renal phenotypes
[8, 10, 31–34]. Using mass spectrometry analysis [9],
we measured choline, carnitine, betaine, and TMAO
levels in fasting serum and identified four significant
associations (FDR <0.05) with unique taxa (three with
TMAO and one with betaine) and eight associations
with OTUs (six with betaine, one with choline, and one
with carnitine) (Fig. 2; Additional file 1: Tables S5 and S6;
Additional file 2: Figure S3). We confirmed previously de-
tected associations between TMAO and the abundance of
Peptococcaceae (P = 4.67 × 10−4) and Prevotella (P = 0.004)
(Fig. 2) [12, 35]. Interestingly, we also observed a negative
association between TMAO and the abundance of
common gut commensal Faecalibacterium prausnitzii
(P = 0.006; FDR <0.08). Decreased abundance of F.
prausnitzii has been linked to dysbiosis in several hu-
man disorders, including obesity, diabetes, and several
immune-related diseases [36, 37]. Our data also con-
firmed a previously reported association between TMAO
and creatinine levels, but in addition we found significant
associations with valine, acetate, and unsaturated and
omega-3 fatty acids levels (Additional file 1: Table S9;
Additional file 2: Figure S5).
OTU co-occurrence network and metabolite associations
The human gut is a complex and dynamic ecosystem
consisting of a diverse collection of microorganisms with
a variety of functional relationships. In order to detect
relationships between different members of the gut
microbiome and their potential combined effect on
metabolic output, we constructed a network of co-
occurrence OTUs and interrogated the network for
modules using weighted gene co-expression network
analysis (WGCNA) (see “Methods”; Fig. 3a, b). The
complete list of OTUs and their module organization is
available in Additional file 1: Tables S10 and S11. Phylo-
genetically related OTUs were observed to cluster into
the same modules preferentially, although each module
also included phylogenetically distinct OTUs from different
taxa. Therefore, in addition to phylogenetic relatedness,
the formation of modules depended upon additional
ecological affinities, reflecting complementary conver-
gent functionality.
The module–metabolite associations confirmed pre-
viously detected metabolite–taxa relationships. For ex-
ample, the blue module, which contains OTUs from
unclassified Clostridales, Tenericutes, Methanobrevibacter,
and Christensenellaceae, is positively correlated with acet-
ate, glutamine, and polyunsaturated fatty acids, whereas
the yellow module, representing OTUs mostly from
Blautia, is negatively correlated with acetate and other
traits associated with the blue module (Fig. 3c). All these
associations were detected with single taxonomy and/or
OTUs (Additional file 1: Tables S5 and S6). However, both
modules also included several other OTUs from different
taxa, providing further insights for metabolically import-
ant relationships.
The gut microbiota relationships with obese and
impaired glucose tolerance phenotypes
We next assessed the associations of gut microbiomes
with obese and pre-diabetic states by subdividing indi-
viduals based on BMI and the entire range of fasting and
2-h plasma glucose tolerance tests. The average BMI of
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the 531 subjects was 27.92 (±0.16), where 100 subjects
(19%) had a BMI <25 and 132 (25%) had a BMI >30.
The pre-diabetic state includes individuals with impaired
fasting glucose (IFG), impaired glucose tolerance (IGT),
or both (see “Methods” for details) [38]. Based on these
criteria, 164 subjects (31%) had normal glucose tolerance
(NGT) and 352 had been classified as in a pre-diabetic
stage (pre-T2D), from which 287 (54%) had IFG, 15
(2.8%) had isolated IGT, and 50 (9.4%) had a combin-
ation of IFG and IGT. A total of 15 individuals had
newly diagnosed T2D in follow-up visits and these indi-
viduals were excluded from the analysis. The character-
istics of these subjects are shown in Additional file 1:
Table S12.
We first evaluated bacterial richness, diversity, and dif-
ferences in the ratio of Firmicutes to Bacteroidetes in
subjects with different body weights and predisposition to
T2D based on OGTT. No significant differences were de-
tected in either bacterial richness or in the ratio of Firmi-
cutes to Bacteroidetes (Additional file 2: Figure S6a, b).
However, several differences were observed in gut micro-
biota composition between subjects with extreme BMI
and between NGT and pre-T2D (Fig. 4a, b; Additional
file 2: Figure S6c). For example, subjects with high BMI
had significantly higher abundance of family Tissierella-
cea and genus Blautia and decreased abundances of Ar-
chaea (Methanobrevibacter) (Fig. 4a). Pre-diabetic subjects,
however, had higher abundances of Anaerostipes and lower
a
c
b
Fig. 3 OTU co-occurrence network and module-trait associations. a OTU co-occurrence network where OTU (nodes) are colored according to the
phyla to which they belong. Blue edges correspond to positive correlations and red edges to negative correlations. Any resulting correlations with
p value ≥0.01 and abs(r) <0.3 were removed. b OTU co-occurrence network were OTU (nodes) are colored according to WGCNA module colors.
c Module–trait associations are shown. Each cell of the matrix contains the correlation between one OTU module and a metabolic trait, and the
corresponding p value. The table is color-coded by correlation according to the color legend (red for positive correlations and green for negative
correlations). FA fatty acids, DHA docosahexaenoic acid, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid, GlycA glycoprotein
acetyls, TMAO trimethyl N-oxide
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abundances of an OTU from families Ruminococcaceae
and Christencenellacea and genus Methanobrevibacter
(Fig. 4b). Both the methanogen Methanobrevibacter and
Christencenellacea have been associated with a lean pheno-
type in previous studies [6, 16, 19, 39].
Using a multivariate regression model we tested
whether obesity and pre-T2D affect associations between
individual microbial taxa and metabolites, and whether
there was interaction between obese/pre-T2D status and
microbial taxa. For example, in obese subjects, the
higher abundance of Bacteroidales was associated with
lower HOMA-IR and the higher abundance of Collinsella
with higher levels of glycerol and phenylalanine, and in
lean subjects the effect was opposite (Fig. 4c). Also,
the abundance of Coprobacillus relative to plasma leu-
cine concentrations depended on the pre-T2D status
(FDR <0.05) (Fig. 4d). Finally, we also constructed
OTU co-occurrence networks separately for subjects
with NGT and for pre-T2D as defined by OGTTs. Our
data show clear differences between interactions of
OTUs in both networks (Additional file 1: Table S13;
Additional file 2: Figure S7a). A module preservation
analysis indicated modules that are unique only for
pre-T2D individuals. For example, a tan module, which
contains mostly OTUs from family Ruminococcacea
and genera Ruminococcus and Oscillospira, is strongly
correlated with glucose levels only in pre-T2D subjects
(Additional file 2: Figure S7b–d).
Discussion
We investigated the associations of gut microbiota with
a large number of metabolically relevant traits using a
subset of 531 Finnish men the from Metabolic Syn-
drome in Men (METSIM) cohort. The METSIM cohort
(total 10,197 individuals) is one of the largest single-site
population based cohorts and was collected from
Kuopio, Eastern Finland, and established to evaluate
genetic determinants of metabolic traits in middle-aged
men. There is increasing evidence that gut microbiota
are an important factor, in addition to genetic and life
style factors, for the development of obesity, insulin
resistance, T2D, and cardiovascular disease. The gut
Fig. 4 The gut microbiota differences in metabolic phenotypes. Mean proportions of significantly different taxa between individuals with different
BMI values (a) and individuals with different 2-h glucose tolerance test (NGT and pre-T2D) (b). Examples of BMI/OGGT metabolite–microbiota
interaction, where the abundances of Bacteroidales, Collinsella (c) and Coprobacillus (d) exhibit opposite associations in individuals with low versus
high BMI levels or individuals with impaired glucose tolerance test (c). *P≤ 0.01, **P≤ 0.001, ***P≤ 0.0001. BMI body mass index, GT glucose tolerance,
NGT normal glucose tolerance, T2D type 2 diabetes
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microbiome is a complex and metabolically active com-
munity, producing many metabolites which can directly
influence host phenotype. Our study investigated gut
microbiota relationships with a variety of factors that
have profound impacts on the development of metabolic
and cardiovascular traits. We present several new find-
ings. First, we identified a number of associations
between gut microbiota and fasting serum levels of fatty
acids, amino acids, lipids, and glucose. These associa-
tions were detected with both the diversity and richness
of gut microbiota as well as with unique bacteria.
Second, we detected significant associations with fasting
plasma TMAO concentrations, a metabolite derived
from dietary choline and carnitine through the action of
gut microbiota. Third, we identified a group of co-
occurrence microbes and demonstrated that OTU-based
module–trait associations confirm already identified as-
sociations as well as provide some new insights for
microbiota–trait relationships. Finally, we detected al-
tered microbiota composition and significant micro-
biota–metabolite relationships dependent on BMI and
normal or altered oral glucose tolerance. These points
are discussed in turn below.
Mounting evidence in mice and humans shows the
important role of gut microbiota-derived metabolites in
regulating metabolism. Multiple studies have shown that
plasma levels of TMAO, derived from dietary choline
and carnitine through the action of gut microbiota, are
associated with coronary artery disease, stroke, and several
cardiometabolic traits, including increased coagulation
and vascular inflammation [8, 31–33]. Consistent with
previous findings in both mice and humans, we found that
the plasma TMAO concentrations were significantly asso-
ciated with Prevotella and Peptococcaceae. Additionally,
we saw a significant positive correlation between plasma
TMAO concentrations with unclassified Clostridales
and negative correlation with F. prausnitzii (FDR <0.1).
F. prausnitzii has been shown to exert anti-inflammatory
effects and decreased abundance of it has been noted in
several immune-related diseases.
Our data show the strongest associations between gut
microbiota and acetate and glutamine levels, where a
total of nine unique taxa were significantly associated
with elevated acetate levels. The higher glutamine and
acetate levels were both also associated with significantly
higher bacterial richness. An elevated abundance of unclas-
sified Clostridales was associated with elevated glutamine
levels and negatively associated with inflammation-related
circulating levels of glycoprotein acetyls (mainly alpha-1-
acid glycoprotein). The phylum Tenericutes (mainly repre-
sented by order RF-39 and ML615J_28) and family
Christensenellaceae were among the top taxa that showed
association with elevated acetate levels. Both taxa have
been previously reported to be associated with low BMI
and TG and higher HDL levels [16, 20]. In the current
study we were only able to confirm order ML615J_28 asso-
ciations with lower TG levels (P = 0.0093), although other
trends were consistent. In addition, we identified novel
strong associations between Christensenellaceae and lower
levels of BCAAs (leucine and isoleucine) and between
Tenericutes and higher ratios of polyunsaturated fatty acids
to total fatty acids.
Acetate is the most common short-chain fatty acid
(SCFA) that is formed during bacterial fermentation of
carbohydrates in the colon [40]. SCFAs are readily
absorbed in the plasma of the host via the intestinal epi-
thelium and thus can serve as an energy source, pre-
dominantly via metabolism in the liver [11, 41]. Previous
studies have shown that both increases and decreases in
plasma SCFA concentrations can be associated with
obesity and metabolic syndrome [42]. It has been shown
that prebiotic fructooligosaccharides and inulin increase
the levels of acetate and that this is associated with re-
duced body weight and fat mass, decreased diabetes, and
a lower food intake [43, 44]. However, recent work by
Perry et al. [45] showed that increased production of
acetate by an altered gut microbiota in rodents leads to
activation of the parasympathetic nervous system and
stimulation of insulin secretion. These studies indicate
that the role of acetate in driving obesity depends on the
gut microbiota composition and on dietary fiber intake.
Several studies have indicated influences of bacterial
taxa on lipid and fatty acid levels [20, 46]. The serum
fatty acid profile is determined by both diet and host fac-
tors, such as endogenous fatty acid metabolism [47].
The Western diet, rich in simple carbohydrates and fat,
markedly affects the gut microbiota ecosystem at the
compositional and functional levels [3, 14, 48, 49].
Elevated levels of lipids and free fatty acids are known
risk factors for metabolic syndrome, insulin resistance,
and obesity [50]. However, dietary fatty acids differ in
structure and have been shown to exert opposite meta-
bolic effects [51, 52]. Our data show that fasting serum
levels of glycerol, monounsaturated fatty acids, and satu-
rated fatty acids are strongly associated with increased
abundance of Blautia and Dorea and decreased abun-
dance of Coprococcus and Peptococcaceae, whereas the
same taxa show opposite associations with polyunsatur-
ated fatty acids, including omega-6 and DHA and
omega-3 and linoleic acid. Several OTUs from genus
Blautia were also positively associated with BCAA
(isoleucine and leucine), alanine, glycerol, and pyruvate
levels. Blautia is a common gut habitant, an acetogen
that belongs to the family Lachnospiraceae, which is one
of the major taxonomic groups of the human gut micro-
biota that degrade complex polysaccharides to SCFAs.
Blautia has the ability to ferment a large variety of or-
ganic substrates, enabling flexible growth in the colon.
Org et al. Genome Biology  (2017) 18:70 Page 8 of 14
Bacteria in the Blautia genus have been associated with
both decreased and increased obesity and Crohn’s dis-
ease [53, 54]. Our data also showed increased abundance
of Blautia in individuals with high BMI levels (Fig. 4a).
Interestingly, a recent study detected an association be-
tween Blautia and human genetic variants in a genomic
region that has been associated with obesity and BMI
[55]. Since there is great diversity among Blautia oligo-
types, suggesting that the genus represents strains that
comprise a variety of metabolic capacities optimized for
a host and a host environment [56].
Complex interactions exist between gut microbiota
and metabolites. Transient changes in the intestinal eco-
system occur throughout life and are affected by several
factors, the most by dietary components. Consumption
of fat- and sugar-rich diets modifies the gut microbiota
community, which triggers changes in host metabolic
pathways and ultimately affects metabolic state. TMAO
is a good example, where multiple bacterial enzymes are
linked to specific biochemical transformations by the
host. However, the exact molecular relationship among
microbe-derived gut metabolites, how microbes affect
host signaling pathways, and host physiology are still
poorly understood. Our data are correlative and there-
fore we are unable to determine the functional potential
of the microbial community. Further studies (metage-
nomic and functional studies) will be required in order
to understand the exact link between microbiota, metabo-
lites, and their link with host health.
Bacteria in the gut constitute a complex ecosystem in
which different species exhibit specialized functions and
interact as a community. Therefore, genetic studies of
communities, as defined by co-occurrence or some other
measures, may provide a better global picture of the
functional variation that occurs in populations [57]. We
identified modules of microbial communities based on
co-occurrence and used these groups to identify associa-
tions with traits. These generally confirmed similar asso-
ciations observed with single taxa or OTUs; for instance,
OTUs that belong to blue and yellow modules have op-
posite effects with traits and these modules contain taxa
that showed significant associations with the same traits
(Additional file 1: Table S11). In addition, module-based
associations also pointed to some new associations that
were missed with single taxa or OTU-based associations.
The METSIM study has been established to evaluate
important determinants of metabolic and cardiovascular
traits. T2D is preceded by a long pre-diabetic state char-
acterized by mild elevation of fasting and/or postpran-
dial glucose levels. Since this asymptomatic stage may
last for years, it’s important to determine characteristics
that associate with impaired glucose metabolism. In this
study the risk of T2D was assessed using OGTTs and
54% of subjects had either impaired fasting glucose
(IFG) and/or impaired glucose tolerance (IGT). We were
unable to detect significant differences in bacterial rich-
ness as well as changes in the ratio of Firmicutes to Bac-
teroidetes, parameters that are usually linked to obesity
and T2D phenotypes. The 16S rRNA gene captures
broad shifts in community diversity over time, but with
limited resolution and lower sensitivity compared to
metagenomic data [58]. Therefore, metagenomic ap-
proaches provide better estimates of the extent of micro-
bial diversity and richness. However, several taxa showed
significantly different abundances between lean and
obese subjects and individuals with impaired glucose
tolerance. Moreover, we also showed specific gut micro-
biota–metabolite interactions within these groups.
Finally, we were able to confirm some previously de-
tected associations with plasma lipids. For example, the
increased abundance of Methanobacteriaceae and genus
Coprococcus was associated with lower levels of TGs. In
addition, novel significant associations were detected
between Methanobacteriaceae and lower levels of gly-
cerol and total and monounsaturated fatty acid levels
(FDR <0.1). In our cohort 40% of subjects had significant
levels of Methanobacteriaceae, a common methanogen
which recycles hydrogen by combining it with carbon di-
oxide to form methane. Methanobacteriaceae have been
associated with reduced levels of obesity [59]. Consistent
with our associations with TG levels, inhibitory effects of
saturated fatty acids on methanogenesis have been re-
cently reported [60]. However, we were unable to detect
any significant associations with HDL and total cholesterol
levels. The observed inconsistencies may indicate either
limited power to detect relationships, variations between
study designs, and/or the existence of population-specific
associations. The METSIM cohort involves only middle-
aged Finnish men, whereas previously reported population-
based studies from Europe report findings for both genders
over a larger age distribution. The inconsistencies are also
commonly seen in animal studies, where mice are main-
tained in highly controlled environments with similar diets.
In the current study, all stool samples were collected in the
clinic at the same time as all measurements and blood were
taken from the Kuopio region of Eastern Finland. This
population is a genetically relatively homogeneous sub-
isolate, which originated from a limited number of founder
ancestors and is, therefore, enriched in specific genetic
variants. Additional population-based cohort studies are
needed to determine whether there are in fact substantial
differences in predictors of fecal sample-derived microbiota
between populations. Importantly, our study involved
only middle-aged Finnish men and therefore we cannot
exclude the possibility that some of the detected associ-
ations are gender-specific. Recent evidence clearly indi-
cates gender differences in bacterial richness, diversity,
and composition [19, 61–63].
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Conclusions
Our study provides a strong indication that several
cardio-metabolically relevant traits and metabolites are
modulated by the action of gut microbiota. We have
identified a number of novel relationships between gut
microbes and different circulating metabolites, where
some of these interactions could predict a pre-diabetic
state. Our data provide a significant biological resource
and novel avenues for further studies. Further functional
and mechanistic investigations are needed in order to
clarify relationships between microbial communities
and specific cardio-metabolic phenotypes. The exten-
sive clinical and molecular characterization of the
METSIM cohort, as well as its homogenous nature,
make it particularly useful for understanding host–
microbiota relationships.
Methods
Sample collection and characterization
A total of 531 men from the ongoing population-based
cross-sectional METSIM study were included in the
current study. METSIM is a randomly selected cohort of
unrelated men (aged 45–70 years) selected from the
population register of the town of Kuopio in Eastern
Finland (population 95,000). Our subset of participants
took part in a 7-year follow-up study. The study was de-
signed to determine the prevalence and genetic determi-
nants of a wide spectrum of metabolic and cardiovascular
diseases (metabolic syndrome, T2D, impaired glucose
tolerance, impaired fasting glucose, hypertension, obesity,
dyslipidemia, coronary heart disease, stroke, and periphe-
ral vascular disease). Every participant had a 1-day out-
patient visit to the Clinical Research Unit at the University
of Kuopio, including an interview about the history of pre-
vious diseases, current health status, and drug treatment.
Each participants’ height, weight, waist to hip circumfer-
ence, and blood pressure were measured together with an
evaluation of glucose tolerance and cardiovascular risk
factors. The study protocol has been previously described
(Stancáková et al. [21]). Characteristics of the subjects in-
cluded in this study are shown in Table 1. Fasting blood
samples were drawn after 12 h of fasting followed by an
oral glucose tolerance test (OGTT). Stool samples were
provided during their evaluation at University of Kuopio
Hospital and immediately stored at −80 °C. All subjects
have given written informed consent and the study was
approved by the Ethics Committee of the University of
Kuopio and was in accordance with the Helsinki
Declaration.
Sample preparation, sequencing, and data processing
Microbial DNA was extracted from a total of 531 frozen
fecal samples using the PowerSoil DNA Isolation Kit
(MO BIO Laboratories, Carlsbad, CA, USA) following
the manufacturer’s instructions. Microbial DNA was ex-
tracted and the 16S rRNA gene was amplified using the
515 F/806R primer set targeting the V4 hypervariable re-
gion and the DNA sequenced using the Illumina MiSeq
platform as previously described [15]. 16S rRNA sequen-
cing data for the 531 samples are available in the Sequence
Read Archive (SRA) under accession number SRP097785
(https://www.ncbi.nlm.nih.gov/sra/?term=SRP097785).
De-multiplexing 16S rRNA gene sequences, quality
control, and OTU binning were performed using the
open source pipeline Quantitative Insights Into Micro-
bial Ecology (QIIME) version 1.7.0 [64, 65]. The total
number of sequencing reads was 12,785,442 (an average
of 21,543 reads per sample) with an average length of
153 base pairs. Sequences were binned into OTUs based
on 97% identity using UCLUST [66] against the Green-
genes reference database (version 13.8) [67]. Each
sample’s sequences were rarefied to 10,000 reads per
strain to reduce the effect of sequencing depth. Micro-
bial composition at each taxonomic level was defined
using the summarize_taxa function in QIIME. To ensure
comprehensive analysis, we sequenced biological repli-
cates on 13 samples and observed high reproducibility
(Additional file 2: Figure S1b).
Metabolite measurements
Fasting serum samples were collected in the clinic and
stored at −80 °C. These were thawed overnight in a
refrigerator prior to analysis for lipids, lipoproteins, fatty
acids, amino acids, and glycolysis precursor molecules
listed in Additional file 1: Table S1 using a NMR
spectroscopy platform [25, 68, 69]. Stable isotope dilu-
tion liquid chromatography with on-line tandem mass
spectrometry (LC-MS/MS) was used for quantification
of plasma TMAO, choline, betaine, and carnitine as pre-
viously described [9].
Glucose metabolism assessment
Plasma glucose was measured by enzymatic hexokinase
photometric assay (Konelab Systems reagents; Thermo
Fisher Scientific, Vantaa, Finland). HbA1c was analyzed
with a Tosoh G7 glycohemoglobin analyzer (Tosoh
Bioscience, San Francisco, CA, USA). Plasma insulin
concentrations were measured by a luminometric im-
munoassay measurement (ADVIA Centaur Insulin IRI,
no. 02230141; Siemens Medical Solutions Diagnostics,
Tarrytown, NY, USA). HOMA-IR calculation was per-
formed according to the formula: Concentration of
fasting blood glucose (mmol/l) × Concentration of
fasting blood insulin (mU/l)/22.5. Insulin resistance
(IR) was diagnosed if HOMA-IR >2.5.
A 75-g OGTT was performed with blood glucose
measurement before glucose intake and 2 h later. Pa-
tients were divided into three groups depending on the
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glucose metabolism deviation degree: i) individuals with-
out glucose intolerance (fasting glucose <5.6 mmol/l and
2-h glucose is <7.8 mmol/l); ii) individuals with pre-
diabetes (pre-T2D), impaired fasting glucose and/or
impaired glucose tolerance (5.6 to 6.9 mmol/l and 2-h
glucose from 7.8 to 11.0 mmol/l); and iii) individuals
with newly diagnosed T2D at the clinical visit (fasting
glucose ≥7.0 mmol/l or 2-h glucose ≥11.1 mmol/l). Indi-
viduals with T1D were excluded from the study.
Statistical analysis
Alpha-diversity (the number of observed genera (richness),
Pielou’s index (evenness), and Fisher’s alpha (diversity) and
beta-diversity (Bray–Curtis dissimilarities) indices were
generated using vegdist and diversity functions in the vegan
R package (version 2.3-2). We assessed how many varia-
tions of Bray–Curtis distance can be explained by each of
the 60 traits using the function adonis from the R package
vegan. The p value was determined by 1000× permutations
and was further adjusted for multiple testing of 60 traits
using the Benjamini and Hochberg method. The total
variation explained was also calculated per category (fatty
acids, glycolysis-related metabolites, amino acids, ketone
bodies) and for all traits together. The association analysis
was assessed by the Spearman correlation between each
trait and each diversity or richness measure. The p values
were further adjusted for multiple testing of 60 traits using
the Benjamini and Hochberg method.
The contribution of each genus and metabolite to
microbiome variation was derived from canonical cor-
respondence analysis (CCA) using both raw as well as
normalized genus abundances. CCA was performed
using the vegan R package function cca, which performs
ordination based on abundances and variations of each
taxa. Covariates of microbiome variation were identified
by calculating the association between traits and genus-
level community ordination (principal component ana-
lysis based on Bray–Curtis dissimilarity) with the enfit
function in the vegan R package (10,000 permutations,
FDR 5%). Overall, 60 metadata covariates were identi-
fied. Their combined effect size was estimated with the
bioenv functions in the vegan package. Microbiome co-
variates were further tested for associations with alpha-
diversity measures and abundance of genera.
To test the association for each taxonomy and species,
we first filtered low abundance species and did our analysis
using 321 OTUs (shared in more than 50% of samples).
The percentage of each species was arcsine-square root-
transformed by taking the arcsine of the square root of the
proportional value of each species. The associations of indi-
vidual species with each factor were assessed using boosted
additive generalized linear models available in the MaAsLin
R package with 5% significance level after multiple testing
correction. MaAsLin is a multivariate statistical framework
that finds associations between clinical metadata and mi-
crobial community abundance or function. In our analysis
we used the default settings of MaAsLin.
Co-occurrence network analysis
Weighted gene co-expression network analysis (WGCNA)
[70] was used to generate a co-occurrence network based
on the OTU arcsine-square root-transformed count data.
Briefly, we considered a signed network and chose the
minimal beta value satisfying the scale free topology
criteria (optimal beta = 6). We set up deepSplit = 2 and
minModuleSize = 10 as parameters for the dynamic tree
cut function [71]. The module eigenOTU defined as the
first principle component of a module was used to calcu-
late the Pearson correlation between a module and a
metabolic trait. Significance of the correlation was deter-
mined by a Student asymptotic p value. Visualization of
the network was performed using the gplot function avail-
able in the sna R package.
For co-occurrence network comparisons, we con-
structed networks in pre-T2D and NGS conditions using
the same criteria as described above. We randomly
chose 100 samples in both conditions to ensure the
same statistical power in network estimation. Module
preservation was assessed using Z-summary as imple-
mented in the WGCNA R package [72]. Briefly, this
statistic evaluates the module preservation based on
density and connectivity criteria and defined a preserva-
tion cutoff by randomly permuting the module labels in
the test network (in the present study we used 1000 per-
mutations in the test network, e.g., NGS condition).
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